Eli Lilly And Co (NYSE:LLY) Shares Bought by Penserra Capital Management LLC

Penserra Capital Management LLC grew its stake in shares of Eli Lilly And Co (NYSE:LLY) by 65.0% in the 3rd quarter, Holdings Channel reports. The firm owned 693 shares of the company’s stock after acquiring an additional 273 shares during the quarter. Penserra Capital Management LLC’s holdings in Eli Lilly And Co were worth $77,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in LLY. Selective Wealth Management Inc. acquired a new stake in Eli Lilly And Co in the third quarter worth $25,000. Enterprise Trust & Investment Co acquired a new position in shares of Eli Lilly And Co during the third quarter valued at $27,000. Garrett Wealth Advisory Group LLC acquired a new position in shares of Eli Lilly And Co during the third quarter valued at $29,000. Candriam Luxembourg S.C.A. boosted its holdings in shares of Eli Lilly And Co by 47.7% during the third quarter. Candriam Luxembourg S.C.A. now owns 270,304 shares of the company’s stock valued at $30,000 after acquiring an additional 87,250 shares during the period. Finally, Prestige Wealth Management Group LLC bought a new position in shares of Eli Lilly And Co during the second quarter worth about $34,000. Institutional investors and hedge funds own 76.51% of the company’s stock.

LLY stock opened at $117.61 on Wednesday. The firm’s 50-day moving average is $112.90 and its two-hundred day moving average is $112.47. The company has a market capitalization of $112.67 billion, a price-to-earnings ratio of 21.19, a price-to-earnings-growth ratio of 1.91 and a beta of 0.16. Eli Lilly And Co has a 52 week low of $101.36 and a 52 week high of $132.13. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 4.09.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The business had revenue of $5.48 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same period last year, the firm posted $1.39 earnings per share. The business’s revenue was up 3.2% on a year-over-year basis. On average, equities research analysts predict that Eli Lilly And Co will post 5.79 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $0.645 dividend. The ex-dividend date is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.19%. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 48,953 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $117.51, for a total value of $5,752,467.03. Following the completion of the sale, the insider now directly owns 115,430,304 shares of the company’s stock, valued at approximately $13,564,215,023.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 4,500 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $117.00, for a total transaction of $526,500.00. Following the completion of the sale, the senior vice president now directly owns 33,806 shares of the company’s stock, valued at $3,955,302. The disclosure for this sale can be found here. Over the last 90 days, insiders acquired 8,405 shares of company stock valued at $909,004 and sold 872,106 shares valued at $100,638,510. Corporate insiders own 0.11% of the company’s stock.

A number of research firms recently weighed in on LLY. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday, November 8th. Bank of America initiated coverage on shares of Eli Lilly And Co in a research note on Wednesday, October 16th. They set a “buy” rating and a $133.00 target price for the company. UBS Group dropped their price target on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $143.00 price target on shares of Eli Lilly And Co in a report on Monday. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $130.03.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Why is momentum important to successful trading?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.